Mavenir Teams With NVIDIA and Amazon Web Services to Deliver Generative AI Co-Pilot for Communications Service Providers
11.6.2024 16:00:00 EEST | Business Wire | Press release
Mavenir, the cloud-native network infrastructure provider building the future of networks, today announced that it has pioneered a breakthrough Operations Co-Pilot that harnesses the power of generative AI (GenAI) to improve service-level agreements (SLAs) and optimize operational efficiency for communications service providers (CSPs). The innovation, which has been developed in collaboration with NVIDIA and Amazon Web Services (AWS), showcases the potential of GenAI to effectively define a Service Assurance AI/Ops Platform – reducing the burden on operations, support and maintenance teams and enhancing their ability to meet SLAs.
Mavenir’s Operations Co-Pilot for RAN Service Assurance (RSA) automates network troubleshooting, enabling mobile network operators to rapidly and accurately anticipate network issues and address detected network impairments before they become critical. The Operations Co-Pilot significantly reduces manual debugging effort, development and maintenance lead times to enhance IT operations, service availability and delivery for increasingly complex mobile networks.
Utilizing the power of GenAI with large language models (LLMs) trained on detailed key performance indicators (KPIs), counters, logs and traces from network infrastructure, Mavenir, together with NVIDIA and AWS, is creating a suite of Operations Co-Pilot solutions that will transform the operations management of telecom networks through intelligent automation. This new framework – built on NVIDIA Tensor Core GPUs and the NVIDIA AI Enterprise software platform for generative AI running on AWS – leverages Mavenir’s Open RAN architecture to provide accessibility into multiple open interfaces that can deliver the data needed to train and optimize domain-specific telecom LLMs.
Mavenir’s Chief Technology and Strategy Officer Bejoy Pankajakshan commented: “Our new Operations Co-Pilot framework has the potential to be a game-changer for operators, delivering a wealth of fault prediction and root cause analysis capabilities with AI-powered accuracy and speed. This industry-first solution is built on the transformative foundation of NVIDIA GPUs operating on AWS and enabled by Mavenir data, which can be accessed via numerous interfaces in the Open RAN and in the Packet Core for complete end-to-end visibility.”
He added: “The three key use cases of Core Dump Analysis, Log Similarity Search feature and Log Anomaly Detection can be used together to maximize the automated efficiency gains. Combining information from these trained LLMs will provide broader and deeper coverage of all fault and anomaly scenarios, enabling very early prediction of potential problems in the network. Moreover, as these solutions evolve, the models have the ability to continuously learn and optimize based on user feedback and iterative training with further logs, KPIs and traces, promising even greater gains.”
“In today’s fast-paced digital landscape, generative AI is a force multiplier for enterprises everywhere,” said Chris Penrose, global head of business development for telco at NVIDIA. “Mavenir’s framework, built on the NVIDIA AI Enterprise platform for streamlining the development and deployment of AI, will unlock a new level of operational efficiency for communications service providers.”
Notes to editors: Watch the video overview: Mavenir’s Operations Co-Pilot for RAN Service Assurance (RSA)
About Mavenir:
Mavenir is building the future of networks today with cloud-native, AI-enabled solutions which are green by design, empowering operators to realize the benefits of 5G and achieve intelligent, automated, programmable networks. As the pioneer of Open RAN and a proven industry disruptor, Mavenir’s award-winning solutions are delivering automation and monetization across mobile networks globally, accelerating software network transformation for 300+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. For more information, please visit www.mavenir.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240610302138/en/
Contacts
Mavenir PR Contacts:
Emmanuela Spiteri
PR@mavenir.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe atopic dermatitis, sustained through Week 52.1 The results will be presented at The Pediatric Dermatology Research Alliance (PeDRA) Annual Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014705800/en/ Up to 25% of children are affected by atopic dermatitis - the most common inflammatory skin disorder in this population - and around one-third of these children have moderate-to-severe disease.11,12 Atopic dermatitis creates a high burden for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school, and social confidence.2-8 Despite the high prevalence and significant burden, treatment options are
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 03:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re excited at the potential to fundamentally change how NT1 is managed across Japan and China,” said Giles Platford, president, International, Takeda. “We’ve heard from patients how ORZEYFUL has improved their daily functioning and quality of life, enormously meaningful outcomes for a condition known to impact many aspects of a person’s life, including work, education and social interactions.”1,2,3,4,5 NT1 is a chronic, rare neurological disease driven by orexin deficiency. People experience a range of symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disr
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 03:10:00 EEST | Press release
Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to expand treatment options for patients with IBD.2,3 On October 18, Celltrion will host a symposium titled "Navigating the Treatment Journey with Subcutaneous Infliximab Across Clinical Scenarios," Chaired by Professor Peter M. Irving of King's College London, UK, a leading IBD expert. Celltrion will also host two MTE sessions at its booth. In the firs
ProcureTEX Returns for Its Second Year, Bringing AI and Best-of-Breed Procurement Technology to Amsterdam14.10.2026 19:26:00 EEST | Press release
ProcureTEX, the community-driven event for best-of-breed procurement technology, returns for its second year on November 3, 2026, at Circa in Amsterdam. Following its London debut in 2025, the event sharpens its focus on how AI is reshaping procurement. It will bring together over 250 procurement leaders and digital transformation teams from large enterprises, with vetted best-of-breed technology providers, to see AI agents and interoperable tools working together on real enterprise challenges. Co-founded by Beroe, Keelvar and Zip, the event is built on the belief that the future of procurement isn’t a monolithic all-in-one suite, but an ecosystem of best-of-breed tools working together. It is designed for procurement and enterprise leaders seeking scalable, modern solutions, whether they’re driving transformation, frustrated with outdated tools, or looking to connect with peers solving similar problems and putting AI to work. Renowned technology analyst and former Andreessen Horowitz
eM Client 11 Launches: A European Outlook Alternative Bringing AI Freedom, Digital Sovereignty, and Next-Generation Productivity14.10.2026 19:16:00 EEST | Press release
eM Client, the European developer of the popular email and productivity application used by millions worldwide, today announced the release of eM Client 11, its most significant update yet. The new version introduces advanced AI capabilities, and major productivity improvements, strengthening its position as an independent alternative to Microsoft Outlook. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014945464/en/ eM Client 11 main window AI Without Vendor Lock-In eM Client 11 introduces a powerful AI Assistant that enables users to search, summarize, organize, and manage emails using natural language. Additional features include personalized AI writing, context-aware quick replies, automatic task and event detection, and AI-powered email rules. Unlike traditional AI integrations, eM Client 11 supports Bring Your Own Key (BYOK), allowing organizations to connect compatible AI providers and models of their choice. The re
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom